ArticleClinical investigation
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.
Article in Clinical investigation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Unsupervised home spirometryEuropean respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2021Pooled it
- Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Trial
- A chronicInfection and immunity · 2025Article
- Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.Frontiers in pediatrics · 2022Review
- Cystic Fibrosis Human Organs-on-a-Chip.Micromachines · 2021Review
- Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Building global development strategies for cf therapeutics during a transitional cftr modulator era.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020Review
- Review
- Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.Respirology (Carlton, Vic.) · 2018Article
- Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.Pediatric pulmonology · 2017Article
- Use of FEVJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017Review
- Chest imaging in cystic fibrosis studies: What counts, and can be counted?Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017Review
- IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016Article
- Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015Article
- Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study.BMC pulmonary medicine · 2015Article
- Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015Article
- Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.The Journal of pediatrics · 2014Article
- State of progress in treating cystic fibrosis respiratory disease.BMC medicine · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cystic fibrosis (CF) is a complex genetic disease characterized by death from loss of lung function. Therapies target pathophysiologic changes associated with pulmonary disease progression. Although therapeutic mechanisms differ, efficacy demonstration is limited to a few accepted outcome measures, each with shortcomings that are becoming more pronounced as CF population health improves. Pulmonary function improvement (as forced expiratory volume in 1 s [FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.